What if cancer treatment could find and destroy cancer cells with extraordinary precision while minimizing damage to healthy tissue?

In Part 2 of this special Rx for Biotech series, Dr. Babak Saboury and Dr. Eliot Siegel from United Theranostics explain radioligand therapy (RLT), one of the fastest-growing areas in precision medicine and cancer treatment.

Radioligand therapies combine advanced imaging and targeted radiation to identify, track, and treat cancer cells throughout the body. This emerging field, known as theranostics, allows physicians to "see what they treat and treat what they see."

In this episode, you'll learn:

• What radioligand therapy (RLT) is

• How theranostics works

• The difference between traditional radiation and targeted radiopharmaceutical therapy

• How imaging helps personalize treatment

• Why prostate cancer and neuroendocrine tumor patients are benefiting today

• What patients can expect during treatment

• Common side effects and safety considerations

If you or someone you love has been diagnosed with cancer, this conversation is a good educational primer to one of the most promising advances in oncology.

Subscribe for more patient-focused conversations on cancer treatment, precision medicine, immunotherapy, cell therapy, and healthcare innovation.

#CancerTreatment #RadioligandTherapy #Theranostics #ProstateCancer #NeuroendocrineTumors #PrecisionMedicine

What does it really take to successfully launch a radiopharmaceutical?

In Part 1 of this special roundtable “Rx for Biotech” podcast series, Chris Leidli met with Dr. Babak Saboury and Dr. Eliot Siegel, founders of United Theranostics and nationally recognized leaders in nuclear oncology, to discuss one of the biggest challenges facing the radiopharmaceutical industry today: building the infrastructure to expand patient access to these innovative medicines.

While radioligand therapies (RLTs) and theranostics are generating unprecedented excitement in oncology, many pharmaceutical companies underestimate the complexity of delivering these therapies to patients.

In this episode, we discuss:

• Why only a small percentage of eligible patients currently receive radioligand therapy

• Site readiness, staffing, and infrastructure challenges

• Why traditional pharmaceutical launch models often fail in radiopharmaceuticals

• Building sustainable access for patients

• What pharmaceutical companies should understand before launching an RLT

This conversation offers a front-line perspective on what it will take to scale the future of radiopharmaceutical medicine.

🎧 Subscribe for more conversations on radiopharmaceuticals, precision medicine, oncology, targeted therapies, and advanced therapies.

#Radiopharmaceuticals #RadioligandTherapy #Theranostics #PrecisionMedicine #Oncology #NuclearMedicine #Pharma #Biotech #HealthcareInnovation #RxForBiotech

What if AI could help women better understand their bodies and take control of their health before problems become crises?

In this episode of #RxforBiotech, host Chris Leidli sits down with Kirsten Karchmer, Founder and CEO of Conceivable, to discuss the future of women's health, fertility, hormone health, and personalized medicine.

After helping more than 10,000 women improve their fertility and reproductive health over the past 25 years, Kirsten is now building an AI-powered operating system designed to help women understand the root causes of health challenges rather than simply treating symptoms.

From fertility and PCOS to fatigue, hormone imbalances, perimenopause, and menopause, Conceivable combines artificial intelligence, wearable data, lifestyle insights, and personalized coaching to help women make informed decisions about their health.

In this episode, we discuss:

• Why so many women feel dismissed by the healthcare system

• The future of AI in women's health

• Fertility treatment and reproductive health

• Personalized medicine and hormone optimization

• The role of wearables, biomarkers, and health data

• Menopause, perimenopause, and healthy aging

• How AI can help women become advocates for their own health

• Why understanding the root cause matters more than treating symptoms

Whether you're trying to conceive, navigating hormone changes, managing a chronic condition, or simply interested in the future of healthcare, this conversation offers an inspiring look at how technology can empower women throughout every stage of life.

🎧 Subscribe for more conversations on healthcare innovation, precision medicine, AI, women's health, and advanced therapies.

What if the future of multiple sclerosis treatment could go beyond suppressing inflammation - and actually help protect the brain?

In this episode of Rx for Biotech, host Chris Leidli sits down with Jason Tardio, President & COO of Immunic Therapeutics, to discuss the evolving future of treatment for Multiple Sclerosis (MS), one of the most complex autoimmune and neurodegenerative diseases affecting millions worldwide.

Jason shares his deep experience leading major MS franchises at Biogen and Novartis, explains how MS attacks the brain and spinal cord, and breaks down why many current therapies focus primarily on inflammation but may not fully address the neurodegeneration driving long-term disability.

The conversation also explores Immunic’s lead investigational therapy, vidofludimus calcium, an oral once-daily treatment being studied in Phase 3 clinical trials for relapsing multiple sclerosis. The company believes the therapy may offer a unique dual approach by targeting both neuroinflammation and neurodegeneration.

Topics discussed include:

• What causes multiple sclerosis

• Early symptoms and diagnosis of MS

• How MRI imaging transformed MS care

• Why MS remains difficult to treat

• The difference between inflammation and neurodegeneration

• Oral therapies vs infusions and injectables

• Progressive multiple sclerosis and unmet patient needs

• The future of neuroscience, immunotherapy, and personalized medicine

For patients, caregivers, healthcare providers, and anyone interested in the future of neurology and autoimmune disease treatment, this episode offers an accessible and hopeful look at where MS care may be headed next.

What if your own immune cells could be engineered to fight and even cure cancer?

In this episode of Rx for Biotech, host Chris Leidli sits down with Navneet Majhail, MD, a leading expert in blood cancers, bone marrow transplants, and CAR-T cell therapy, to break down one of the most powerful innovations in modern medicine: CAR-T therapy.

CAR-T therapy is a form of immunotherapy that uses a patient’s own T cells - engineered in a lab - to recognize and destroy cancer. It has already transformed outcomes for patients with leukemia, lymphoma, and multiple myeloma, offering hope where few options previously existed.

But despite its promise, many eligible patients still don’t receive CAR-T therapy due to barriers like access, geography, insurance, and care coordination.

In this conversation, Dr. Majhail explains:

• What CAR-T cell therapy is and how it works

• Why access to treatment remains a major challenge

• The role of bone marrow transplant and cellular therapy networks

• How care is shifting closer to home through community-based treatment models

• The importance of caregivers and support systems during treatment

• What the future holds for CAR-T in solid tumors, autoimmune diseases, and beyond

This episode is a must-watch for patients, caregivers, and anyone interested in the future of personalized cancer treatment, immunotherapy, and advanced therapies

Why is brain cancer so hard to detect and treat - and what if we could change that?

In this episode of Rx for Biotech, host Chris Leidli sits down with Marc Hedrick, CEO of Plus Therapeutics, and Russell Bradley, General Manager of CNSide Diagnostics, to explore a new, integrated approach to treating some of the most challenging cancers in medicine: central nervous system (CNS) cancers, including glioblastoma and leptomeningeal metastases.

Brain and CNS cancers are among the most difficult to treat because of the blood-brain barrier, which prevents most drugs from reaching tumors. In fact, only a small percentage of therapies can effectively cross into the brain—limiting treatment options and outcomes.

Plus Therapeutics is tackling this problem with a novel approach using targeted radiation therapy delivered directly to tumors, bypassing the blood-brain barrier. Their lead program uses a radioactive isotope (rhenium-186) delivered via nanoliposomes, allowing high doses of radiation to reach the tumor while minimizing damage to the rest of the body.

At the same time, CNSide Diagnostics is helping physicians detect cancer earlier and monitor treatment response using an advanced cerebrospinal fluid (CSF) diagnostic test. This highly sensitive test can identify even small numbers of tumor cells—helping doctors make faster, more informed treatment decisions.

Together, this combination of diagnostics + therapeutics + data represents a new model for precision oncology and personalized cancer care.

In this episode, we discuss:

• Why brain cancer is so difficult to treat

• The role of the blood-brain barrier in limiting therapies

• How targeted radiation therapy can improve outcomes

• The importance of early detection and diagnostics

• How monitoring tumor cells can guide treatment decisions

• The future of integrated cancer care (theranostics)

This conversation offers a powerful look at how innovation in both treatment and diagnostics could help improve survival and quality of life for patients with some of the most aggressive cancers.

What if you could get a Transplant and Reset your Immune System in less than 48 Hours?

In this episode of Rx for Biotech, host Chris Leidli sits down with Kevin Caldwell, CEO of Ossium Health, to explore how bone marrow transplants, cell therapy, and bioengineered immune systems are transforming the future of medicine.

Ossium Health is building a first-of-its-kind bone marrow banking platform, using donor-derived cells to make life-saving treatments available on demand. Traditionally, patients can wait months to find a donor match - time many simply don’t have. Ossium is changing that by enabling transplants in as little as 48 hours, dramatically improving access to care.

In this conversation, Kevin explains how bone marrow transplants work, why they are one of the most powerful tools in modern medicine, and how replacing a patient’s blood and immune system can treat diseases like blood cancers and immune disorders.

We also dive into:

• Why most eligible patients never receive a bone marrow transplant

• How off-the-shelf cell therapy could scale life-saving treatments

• The role of the immune system in preventing disease and cancer

• How donor-derived cells could unlock the future of regenerative medicine and longevity

• Why improving immune health may be one of the most powerful ways to extend human life

As cell therapy and regenerative medicine continue to evolve, Ossium’s approach could help shift healthcare from reactive treatment to proactive, personalized immune system care.

📌 Learn more about how to navigate the healthcare system and find the right specialists:

https://therapy4me.ai

What if chemotherapy could target tumors without harming the rest of the body?

In this episode of *Rx for Biotech*, host Chris Leidli sits down with Christina Coughlin, MD, PhD, CEO of Avacta Therapeutics, to explore a new approach to cancer treatment using targeted chemotherapy and precision oncology.

Avacta is developing a novel platform designed to activate powerful cancer drugs only inside the tumor, potentially reducing side effects like damage to the heart, bone marrow, and other healthy tissues. This approach, known as tumor-targeted drug delivery, could redefine how chemotherapy is used across cancers such as triple-negative breast cancer, soft tissue sarcoma, and salivary gland cancer.

Christina shares her journey from early work in CAR-T cell therapy and immuno-oncology to leading Avacta’s innovative pre|CISION peptide drug conjugate platform, including its lead asset AVA6000 (faridoxorubicin) now in clinical trials.

In this conversation, we discuss:

• How targeted chemotherapy works and why it may be safer than traditional chemo

• The role of the immune system and immunotherapy in cancer treatment

• Why improving drug delivery is one of the biggest challenges in oncology

• Key clinical insights from early trials of AVA6000

• What the future of precision medicine and personalized cancer care could look like

As cancer treatment evolves, innovations like Avacta’s platform could help patients receive more effective, less toxic therapies tailored to their biology

📌 Learn more about navigating advanced therapies and personalized care at: [https://www.therapy4me.ai]

#CancerTreatment #PrecisionMedicine #Chemotherapy #Immunotherapy #Oncology #Biotech #TargetedTherapy #Avacta #RxForBiotech

What if a simple blood test could reveal how your body responds to disease - or even help doctors choose the right treatment for you?

In this episode of Rx for Biotech, host Chris Leidli speaks with Mo Jain, MD, PhD, co-founder of Sapient, about how scientists are using advanced biology and artificial intelligence to uncover new biomarkers - the biological signals that can help doctors understand what’s happening inside the body.

Biomarkers are becoming one of the most important tools in precision medicine, helping physicians move beyond one-size-fits-all treatments toward care that is tailored to each patient’s unique biology.

Mo explains how Sapient is analyzing thousands of human samples using advanced technologies to better understand metabolism, disease progression, and how patients respond to therapies. These insights could help improve early diagnosis, guide treatment decisions, and empower patients with more personalized health information.

In this conversation, you’ll learn:

• What biomarkers are and why they matter for patients

• How AI and advanced biology are helping scientists discover new health insights

• Why understanding your body’s metabolism can change how diseases are treated

• How biomarker data could help patients and doctors make better care decisions

As medicine becomes more personalized, having the right biological information may become one of the most powerful tools patients have to advocate for their own care.

For additional patient education and support, visit:

https://therapy4me.ai

In this episode of "Rx for Biotech", host Chris Leidli speaks with Rodney Gillespie, Senior Vice President and U.S. Therapeutic Area Head for Oncology at Novartis, about the rapid evolution of prostate cancer care, including the rise of radioligand therapy and PSMA-targeted treatments like Pluvicto® (lutetium Lu 177 vipivotide tetraxetan).

We discuss:

* How PSMA-targeted radioligand therapy delivers radiation directly to cancer cells

* The role of innovation in advanced and metastatic prostate cancer

* Expanding patient access to cutting-edge therapies

* Why patient advocacy and education matter in modern oncology

As prostate cancer remains one of the most common cancers in men, new treatment approaches like radioligand therapy are redefining what’s possible for patients living with advanced prostate cancer.